Compare SACH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | ACRV |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | 27 | 76 |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 68.5M |
| IPO Year | N/A | 2022 |
| Metric | SACH | ACRV |
|---|---|---|
| Price | $0.80 | $1.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.00 | ★ $11.67 |
| AVG Volume (30 Days) | 133.3K | ★ 449.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.20 |
| 52 Week High | $1.45 | $3.56 |
| Indicator | SACH | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 26.77 | 41.17 |
| Support Level | N/A | $1.38 |
| Resistance Level | $1.12 | $2.15 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 1.87 | 2.70 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.